UPDATE - Lundbeck buys European rights to Alzheimer's drug (at Reuters)

yahoo.com     22-May-2008            

By Gelu Sulugiuc COPENHAGEN, May 22 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO: ) said on Thursday it had acquired the European rights to Myriad Genetics' Flurizan, an experimental Alzheimer's drug it hopes can become the company's next blockbuster. Lundbeck will pay Myriad (MYGN.O:... [read full story]                    


View all news articles about*:
Alzheimer's Behavior Disease Genetics Health Mental Myriad
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies